- Home
- Equipment
- usa california
- drug like molecules
Show results for
Refine by
Drug Like Molecules Equipment Supplied In Usa California
6 equipment items found
Manufactured by:Bexson Biomedical based inSanta Barbara, CALIFORNIA (USA)
Pharmaceutical technology for liquid formulations. A patented 7-Valence Salt revolutionizing small molecule ...
Manufactured by:SomaGenics, Inc. based inSanta Cruz, CALIFORNIA (USA)
RNA interference (RNAi) is a naturally occurring process by which RNA molecules inhibit gene expression either pre- or post-transcriptionally. The discovery of RNAi led to a better understanding of gene regulation and opened the door to exciting new applications in research and therapeutics. The 2006 Nobel price was awarded in recognition of this revolutionary ...
Manufactured by:Entero Therapeutics, Inc. based inBoca Raton, FLORIDA (USA)
FW-ICI-AC is a niclosamide-based, oral, small molecule anti-inflammatory inhibitor therapy for the treatment of immune checkpoint inhibitor (ICI)-associated colitis and diarrhea in metastatic cancer patients. The PASSPORT clinical trial, a Phase 2a study to determine the safety and potential efficacy of niclosamide in the treatment of ICI-AC, received FDA IND clearance in Q4 ...
Manufactured by:Manzanita Pharmaceuticals, Inc. based inWoodside, CALIFORNIA (USA)
Nervelight™, a topical, intraoperative nerve imaging agent that is selective for at-risk nerve tissue in cancer ...
Manufactured by:BenchChem, a brand of Innovation Sciences Inc. based inPasadena, CALIFORNIA (USA)
Nevadensin is a novel small molecule that has been studied for its potential therapeutic applications in medicine. It is a member of the polyphenol family and has a unique structure that makes it attractive for use in various medical applications. It has been studied for its potential anti-cancer, anti-inflammatory, anti-allergic, and other therapeutic ...
Manufactured by:Qualigen Therapeutics, Inc. based inCarlsbad, CALIFORNIA (USA)
Qualigen licensed the G4 selective transcription inhibitor platform from University College London (UCL) in 2022. The licensed technology comprises lead compound QN-302 (formerly SOP1812) and back-up compounds that target regulatory regions of cancer genes that down-regulate gene expression in multiple cancer pathways. Developed by Dr. Stephen Neidle and his group at UCL, the G4 binding concept ...